Real-world evidence of benefits of Soliris for PNH patients

At the 22nd Congress of the European Hematology Association (EHA), researchers presented new data from the International Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry.

Data showed real-world evidence of benefits of treatment with rare diseases specialist Alexion Pharmaceuticals’ (Nasdaq: ALXN) Soliris (eculizumab), a complement inhibitor, for patients with PNH regardless of high disease activity (HDA), and for patients with hemolytic PNH and those with PNH with concurrent aplastic anemia (AA). A consensus-based algorithm developed by international PNH experts for the diagnosis of PNH was also presented.

PNH is an ultra-rare, auto-immune blood disorder that strikes people of all ages, with an average age of onset in the early 30s, and is characterized by complement-mediated hemolysis (destruction of red blood cells). Net product sales of Soliris were up 9.7% to $2.84 billion, for full-year 2016.